Literature DB >> 20674744

Assessment of evidence for a protective role of vitamin D in multiple sclerosis.

Heather E C Hanwell1, Brenda Banwell.   

Abstract

Evidence for a role of vitamin D insufficiency in determining risk in Multiple Sclerosis (MS) is supported by studies in both pediatric- and adult-onset patients. The potential role of vitamin D in modulating MS disease activity is an area of active clinical trials research, and the possibility of primary disease prevention with vitamin D supplementation in early life is an emerging concept. With Sir Austin Bradford Hill's criteria as a framework, the present review assesses the evidence for a causal relationship between vitamin D insufficiency and the pathobiology of MS, and discusses rationale for future clinical trials with vitamin D. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20674744     DOI: 10.1016/j.bbadis.2010.07.017

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  20 in total

Review 1.  Therapies for multiple sclerosis: considerations in the pediatric patient.

Authors:  Brenda Banwell; Amit Bar-Or; Gavin Giovannoni; Russell C Dale; Marc Tardieu
Journal:  Nat Rev Neurol       Date:  2011-01-11       Impact factor: 42.937

Review 2.  Evaluating the Effects of Dietary Interventions on Disease Progression and Symptoms of Adults with Multiple Sclerosis: An Umbrella Review.

Authors:  Abbey R Tredinnick; Yasmine C Probst
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

Review 3.  Vitamin D in systemic and organ-specific autoimmune diseases.

Authors:  Nancy Agmon-Levin; Emanuel Theodor; Ramit Maoz Segal; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

4.  Evaluation of Delta-Aminolevulinic Dehydratase Activity, Oxidative Stress Biomarkers, and Vitamin D Levels in Patients with Multiple Sclerosis.

Authors:  Carla Roberta Nunes Polachini; Roselia Maria Spanevello; Daniela Zanini; Jucimara Baldissarelli; Luciane Belmonte Pereira; Maria Rosa Chitolina Schetinger; Ivana Beatrice Mânica da Cruz; Charles Elias Assmann; Margarete Dulce Bagatini; Vera Maria Morsch
Journal:  Neurotox Res       Date:  2015-12-21       Impact factor: 3.911

5.  Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation.

Authors:  Charles Pierrot-Deseilligny; Sophie Rivaud-Péchoux; Pierre Clerson; Raphaël de Paz; Jean-Claude Souberbielle
Journal:  Ther Adv Neurol Disord       Date:  2012-07       Impact factor: 6.570

6.  Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis.

Authors:  Charles Pierrot-Deseilligny; Jean-Claude Souberbielle
Journal:  Ther Adv Neurol Disord       Date:  2013-03       Impact factor: 6.570

7.  A Method for Simultaneous Determination of 25-Hydroxyvitamin D3 and Its 3-Sulfate in Newborn Plasma by LC/ESI-MS/MS after Derivatization with a Proton-Affinitive Cookson-Type Reagent.

Authors:  Tatsuya Higashi; Mai Yokota; Ayaka Goto; Kenji Komatsu; Takahiro Sugiura; Shoujiro Ogawa; Mamoru Satoh; Fumio Nomura
Journal:  Mass Spectrom (Tokyo)       Date:  2016-08-31

Review 8.  You are what you eat, and so are your children: the impact of micronutrients on the epigenetic programming of offspring.

Authors:  Kimberly Vanhees; Indira G C Vonhögen; Frederik J van Schooten; Roger W L Godschalk
Journal:  Cell Mol Life Sci       Date:  2013-07-27       Impact factor: 9.261

9.  Prevalence and predictors of vitamin D insufficiency in children: a Great Britain population based study.

Authors:  Michael Absoud; Carole Cummins; Ming J Lim; Evangeline Wassmer; Nick Shaw
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

10.  Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses.

Authors:  Louisa E Jeffery; Alice M Wood; Omar S Qureshi; Tie Zheng Hou; David Gardner; Zoe Briggs; Satdip Kaur; Karim Raza; David M Sansom
Journal:  J Immunol       Date:  2012-10-19       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.